AstraZeneca Pharma India announced a robust 39% growth for Q3 FY’25-26 (Oct-Dec ’25), with total revenue reaching INR 6,115.7 Mn. This performance was underpinned by strong execution across Oncology, Biopharmaceuticals, and Rare Disease segments. The company also secured 8 new regulatory approvals over the preceding nine months, further cementing its leadership and commitment to delivering innovative therapies in India.
Q3 FY26 Financial Highlights
AstraZeneca Pharma India Limited reported substantial financial results for the third quarter ending December 31, 2025. Total revenue from operations for the quarter stood at INR 6,115.7 Mn, reflecting a 39% growth compared to the corresponding period last year. Profit before exceptional items and tax for the quarter was INR 450.6 Mn, while the Profit after exceptional item and tax rose to INR 465.4 Mn.
For the nine months ended December 31, 2025, total revenue reached INR 16,969.7 Mn, with Profit after exceptional item and tax at INR 1,940.6 Mn.
Segment Performance Analysis
The growth momentum was consistent across key therapy areas:
- Oncology revenue for the nine months reached INR 12,069.5 Mn.
- Biopharmaceuticals (CVRM, R&I, and V&I) contributed INR 3,834.9 Mn in the nine-month period.
- Rare Disease revenue for the nine months amounted to INR 107.6 Mn.
Key Strategic Milestones and Approvals
The company highlighted significant progress through regulatory achievements over the past nine months:
- Durvalumab received approval for two additional indications in endometrial cancer, including first-line treatment in combination with carboplatin and paclitaxel, and maintenance treatment with Olaparib.
- Durvalumab was also approved for adjuvant treatment in muscle invasive bladder cancer (MIBC).
- The company launched Eculizumab, marking a milestone as the first anti-complement therapy approved in India for Atypical Haemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH).
- Osimertinib gained approval for first-line treatment in combination for locally advanced/metastatic NSCLC, and later for stage III monotherapy use in specific NSCLC patient populations.
- Trastuzumab deruxtecan secured an additional indication for HER2-low and HER2-ultralow metastatic breast cancer.
- Benralizumab received approval for an add-on treatment for relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).
- Sodium Zirconium Cyclosilicate received permission for import and sale for hyperkalaemia management.
Operational Context and Outlook
The company confirmed that site closure activities related to the manufacturing facility continued, resulting in exceptional expense items recognized during the quarter and nine months ended December 31, 2025. Management commentary emphasized disciplined execution and a focus on access to bring long-term value to patients, supported by this strong pipeline delivery.
Auditor Review Conclusion
The unaudited financial results were reviewed by the Statutory Auditors, Price Waterhouse & Co Chartered Accountants LLP. The auditors concluded, based on their review, that the statement appears free of material misstatement in all material respects.
Source: BSE
